Related references
Note: Only part of the references are listed.Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia
Jorge Cortes et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2021)
Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications
Ilma Shakeel et al.
JOURNAL OF DRUG TARGETING (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Sotorasib: First Approval
Hannah A. Blair
DRUGS (2021)
PLK1 and NOTCH Positively Correlate in Melanoma and Their Combined Inhibition Results in Synergistic Modulations of Key Melanoma Pathways
Shengqin Su et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Design of Disruptors of the Hsp90-Cdc37 Interface
Ilda D'Annessa et al.
MOLECULES (2020)
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
Andriy Marusyk et al.
CANCER CELL (2020)
Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma
Roberta Affatato et al.
CANCERS (2020)
Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC
Hao Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Perspective Rational Cancer Treatment Combinations: An Urgent Clinical Need
Julia Boshuizen et al.
MOLECULAR CELL (2020)
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Amer M. Zeidan et al.
CLINICAL CANCER RESEARCH (2020)
Targeting the PLK1-FOXO1 pathway as a novel therapeutic approach for treating advanced prostate cancer
Lilia Gheghiani et al.
SCIENTIFIC REPORTS (2020)
Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma
Yan Li et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2020)
A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer
Lifeng Li et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells
Siyeon Park et al.
CANCER LETTERS (2020)
Combination of Inhibitors of USP7 and PLK1 has a Strong Synergism against Paclitaxel Resistance
Sol-Bi Shin et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Potential Drug-Drug Interactions with Combination Volasertib plus Itraconazole: A Phase I, Fixed-sequence Study in Patients with Solid Tumors
Istvan Lang et al.
CLINICAL THERAPEUTICS (2020)
Dual inhibition of Src and PLK1 regulate sternness and induce apoptosis through Notchl-SOX2 signaling in EGFRvIII positive glioma stern cells (GSCs)
Xuetao Li et al.
EXPERIMENTAL CELL RESEARCH (2020)
Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma
Youjia Han et al.
CANCER LETTERS (2019)
The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?
Guillermo de Carcer
GENES (2019)
A methylation-phosphorylation switch determines Plk1 kinase activity and function in DNA damage repair
Weizhe Li et al.
SCIENCE ADVANCES (2019)
A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma
Mengjiao Wu et al.
EBIOMEDICINE (2019)
Cancer treatment and survivorship statistics, 2019
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer
Shu-Fu Lin et al.
ENDOCRINE-RELATED CANCER (2019)
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer
Antonio Giordano et al.
PLOS ONE (2019)
Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer
Sol-Bi Shin et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer
Peter J. Klauck et al.
BMC CANCER (2018)
Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma
Ting-Ting Liu et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2018)
Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
Fengyi Mao et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Oncogenic addiction to high 26S proteasome level
Peter Tsvetkov et al.
CELL DEATH & DISEASE (2018)
Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of polo-like kinase 1 and microtubule dynamics
Sabrina Noack et al.
Oncotarget (2018)
Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer
Alfiah Noor et al.
Oncotarget (2018)
PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer
Daniela De Martino et al.
CANCER LETTERS (2018)
Plk1 overexpression induces chromosomal instability and suppresses tumor development
Guillermo de Carcer et al.
NATURE COMMUNICATIONS (2018)
Generation and characteristics of a novel “double-hit” high grade B-cell lymphoma cell line DH-My6 with MYC/IGH and BCL6/IGH gene arrangements and potential molecular targeted therapies
Hiroaki Kikuchi et al.
Oncotarget (2018)
PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas
Yuan Ren et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Exploration of the Combination of PLK1 Inhibition with Immunotherapy in Cancer Treatment
Mengyuan Li et al.
JOURNAL OF ONCOLOGY (2018)
Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine
Belen P. Solans et al.
CLINICAL PHARMACOKINETICS (2018)
An open-label, phase II study of the polo-like kinase-1 (P1k-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)
Mark M. Awad et al.
LUNG CANCER (2017)
Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer
Jie Li et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Playing polo during mitosis: PLK1 takes the lead
G. Combes et al.
ONCOGENE (2017)
PLK1, A Potential Target for Cancer Therapy
Zhixian Liu et al.
TRANSLATIONAL ONCOLOGY (2017)
How Hsp90 and Cdc37 Lubricate Kinase Molecular Switches
Kliment A. Verba et al.
TRENDS IN BIOCHEMICAL SCIENCES (2017)
NRAS-mutant melanoma: current challenges and future prospect
Eva Munoz-Couselo et al.
ONCOTARGETS AND THERAPY (2017)
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
T. Terwilliger et al.
BLOOD CANCER JOURNAL (2017)
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Emmet J. Jordan et al.
CANCER DISCOVERY (2017)
Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines
Lilly Magdalena Weiss et al.
ONCOTARGET (2017)
Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms
Tri Nguyen et al.
ONCOTARGET (2017)
Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia
Yoshiya Adachi et al.
ONCOTARGET (2017)
PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas
Robert F. Koncar et al.
ONCOTARGET (2017)
Combination therapy in combating cancer
Reza Bayat Mokhtari et al.
ONCOTARGET (2017)
Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy
Adam C. Palmer et al.
CELL (2017)
Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis
Sebastian Czaplinski et al.
ONCOTARGET (2016)
Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer
Jie Li et al.
CELL CYCLE (2016)
Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration- resistant prostate cancer
Long Chen et al.
CELL CYCLE (2016)
Discovery of Non-ATP-Competitive Inhibitors of Polo-like Kinase1
Taikangxiang Yun et al.
CHEMMEDCHEM (2016)
Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel
Yi-Sheng Chou et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
Rosie Elizabeth Ann Gutteridge et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
Jieqiong Wang et al.
NATURE COMMUNICATIONS (2016)
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations
Yuehong Wang et al.
ONCOTARGET (2016)
Polo-like kinase and its inhibitors: Ready for the match to start?
Neil D. Palmisiano et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors
F. de Braud et al.
ANNALS OF ONCOLOGY (2015)
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Khalid O. Alfarouk et al.
CANCER CELL INTERNATIONAL (2015)
A phase I study of volasertib combined with afatinib, in advanced solid tumors
Jean-Pascal Machiels et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma
Angelika Stehle et al.
CANCER LETTERS (2015)
A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer
Peter M. Ellis et al.
CLINICAL LUNG CANCER (2015)
Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged ≥65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy
Daniel J. DeAngelo et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma
Christian Posch et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins
Valentina Zuco et al.
ONCOTARGET (2015)
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
Hartmut Doehner et al.
BLOOD (2014)
Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance
Valeria Sero et al.
INVESTIGATIONAL NEW DRUGS (2014)
Polo-like kinases: structural variations lead to multiple functions
Sihem Zitouni et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status
Lisa Lange et al.
ONCOTARGET (2014)
Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer
Virginie Maire et al.
CANCER RESEARCH (2013)
Targeting prostate cancer cell lines with polo-like kinase 1 innibitors as a single agent and in combination with histone deacetylase inhibitors
Michel D. Wissing et al.
FASEB JOURNAL (2013)
Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells
Octavian Bucur et al.
PLOS ONE (2013)
NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies
Barbara Valsasina et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN
Martin Leinung et al.
ONCOLOGY LETTERS (2012)
Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536
Karoline V. Gleixner et al.
CANCER RESEARCH (2010)
Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors
Italo Beria et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy Results from an Open-Label, Randomized Phase II Clinical Trial
Martin Sebastian et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Share Paper
